PMID- 23529824
OWN - NLM
STAT- MEDLINE
DCOM- 20140203
LR  - 20211021
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 73
IP  - 5
DP  - 2013 Apr
TI  - Everolimus in combination with exemestane: a review of its use in the treatment 
      of patients with postmenopausal hormone receptor-positive, HER2-negative advanced 
      breast cancer.
PG  - 475-85
LID - 10.1007/s40265-013-0034-2 [doi]
AB  - Oral everolimus (Afinitor((R))) in combination with exemestane is indicated for the 
      treatment of hormone receptor-positive, human epidermal growth factor receptor 
      (HER) 2-negative advanced breast cancer in postmenopausal women after failure of 
      treatment with letrozole or anastrozole (in the USA) or after recurrence of 
      progression following a nonsteroidal aromatase inhibitor (AI) in women without 
      symptomatic visceral disease (in the EU). Everolimus, a selective inhibitor of 
      mammalian target of rapamycin (mTOR), inhibits the downstream signalling events 
      of the mTOR pathway. This review summarizes the pharmacology of everolimus and 
      reviews its efficacy and tolerability when administered in combination with 
      exemestane in postmenopausal women with oestrogen receptor-positive, 
      HER2-negative advanced breast cancer refractory to nonsteroidal AIs. In the 
      well-designed BOLERO-2 study, the addition of everolimus to exemestane was shown 
      to significantly prolong progression-free survival in this patient population. 
      However, treatment-emergent adverse events and treatment discontinuations 
      occurred more frequently with combination therapy than with exemestane alone, 
      suggesting a need for careful benefit/risk assessment prior to initiating 
      therapy. Mature survival data from this study are awaited and additional studies 
      would help to further demonstrate the benefit of combination therapy. 
      Nevertheless, current evidence suggests that everolimus plus exemestane 
      combination therapy may be a useful treatment option in patients with 
      postmenopausal hormone receptor-positive, HER2-negative, advanced breast cancer 
      refractory to nonsteroidal AIs.
FAU - Dhillon, Sohita
AU  - Dhillon S
AD  - Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754 
      Auckland, New Zealand. demail@springer.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Androstadienes)
RN  - 0 (Aromatase Inhibitors)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - NY22HMQ4BX (exemestane)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Androstadienes/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Aromatase Inhibitors/*administration & dosage
MH  - Breast Neoplasms/*drug therapy/mortality/pathology
MH  - Everolimus
MH  - Female
MH  - Humans
MH  - Postmenopause/*drug effects/metabolism
MH  - Randomized Controlled Trials as Topic
MH  - *Receptor, ErbB-2/metabolism
MH  - Secondary Prevention
MH  - Sirolimus/administration & dosage/analogs & derivatives
MH  - Treatment Outcome
EDAT- 2013/03/27 06:00
MHDA- 2014/02/04 06:00
CRDT- 2013/03/27 06:00
PHST- 2013/03/27 06:00 [entrez]
PHST- 2013/03/27 06:00 [pubmed]
PHST- 2014/02/04 06:00 [medline]
AID - 10.1007/s40265-013-0034-2 [doi]
PST - ppublish
SO  - Drugs. 2013 Apr;73(5):475-85. doi: 10.1007/s40265-013-0034-2.